PMID- 17327886
OWN - NLM
STAT- MEDLINE
DCOM- 20071120
LR  - 20220318
IS  - 0893-133X (Print)
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Linking)
VI  - 32
IP  - 10
DP  - 2007 Oct
TI  - Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate 
      of methamphetamine self-administration in rats with prolonged session duration.
PG  - 2238-47
AB  - Aripiprazole is a dopamine (DA) D(2) receptor partial agonist, approved by the 
      Food and Drug Administration (FDA) for the treatment of schizophrenia. DA 
      receptor partial agonists have been previously assessed as potential therapeutic 
      agents for cocaine dependence. The present experiment examined the effect of 
      aripiprazole on methamphetamine self-administration in a rodent model of an 
      increasing drug self-administration with prolonged session duration. Wistar rats 
      were allowed to self-administer methamphetamine (0.05 mg/kg/injection, 
      intravenously) in either 1-h (short access: ShA rats) or 6-h sessions (long 
      access: LgA rats). After 15 sessions, the dose-response function of 
      methamphetamine was determined under either a progressive- or a fixed-ratio 
      schedule. Next, the effect of aripiprazole (0.3-10 mg/kg, subcutaneuously (s.c.)) 
      on the dose-response function was examined. LgA rats exhibited an increasing rate 
      of methamphetamine self-administration. Responding for methamphetamine by LgA 
      rats was higher than that of ShA rats under both schedules. Pretreatment with 
      aripiprazole shifted the dose-response function of methamphetamine to the right 
      in both LgA and ShA rats. However, the effect of aripiprazole was greater in LgA 
      than ShA rats. In in vitro receptor binding assay, no change in the level of D(2) 
      DA receptors in the nucleus accumbens and the striatum was found in any group. 
      The present data suggest increased sensitivity of the dopaminergic system to 
      aripiprazole in LgA rats compared with ShA rats. However, mechanisms other than 
      downregulation of D(2) DA receptors in the nucleus accumbens and the striatum may 
      be responsible for the increased sensitivity of the dopaminergic function in LgA 
      rats.
FAU - Wee, Sunmee
AU  - Wee S
AD  - Committee on Neurobiology of Addictive Disorder, The Scripps Research Institute, 
      La Jolla, CA92037, USA. sunmee@scripps.edu
FAU - Wang, Zhixia
AU  - Wang Z
FAU - Woolverton, William L
AU  - Woolverton WL
FAU - Pulvirenti, Luigi
AU  - Pulvirenti L
FAU - Koob, George F
AU  - Koob GF
LA  - eng
GR  - R01 DA010072-08/DA/NIDA NIH HHS/United States
GR  - R01 DA010352-08/DA/NIDA NIH HHS/United States
GR  - R01 DA010352/DA/NIDA NIH HHS/United States
GR  - R01 DA010072/DA/NIDA NIH HHS/United States
GR  - DA10352/DA/NIDA NIH HHS/United States
GR  - DA010072/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070228
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 0 (Receptors, Dopamine D2)
RN  - 44RAL3456C (Methamphetamine)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Amphetamine-Related Disorders/*drug therapy/metabolism/physiopathology
MH  - Animals
MH  - Antipsychotic Agents/pharmacology
MH  - Aripiprazole
MH  - Brain/*drug effects/metabolism/physiopathology
MH  - Brain Chemistry/drug effects/physiology
MH  - Corpus Striatum/drug effects/metabolism
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects/physiology
MH  - Drug Administration Schedule
MH  - Drug Interactions/physiology
MH  - Male
MH  - Methamphetamine/adverse effects/*antagonists & inhibitors
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Piperazines/*pharmacology
MH  - Quinolones/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Dopamine D2/*agonists/metabolism
MH  - Self Administration
PMC - PMC2747088
MID - NIHMS140618
EDAT- 2007/03/01 09:00
MHDA- 2007/12/06 09:00
PMCR- 2009/09/21
CRDT- 2007/03/01 09:00
PHST- 2007/03/01 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/03/01 09:00 [entrez]
PHST- 2009/09/21 00:00 [pmc-release]
AID - 1301353 [pii]
AID - 10.1038/sj.npp.1301353 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2007 Oct;32(10):2238-47. doi: 10.1038/sj.npp.1301353. 
      Epub 2007 Feb 28.